基底细胞癌的瘤内α-2a干扰素治疗

Intralesional alfa-2a interferon therapy for basal cell carcinoma.

作者信息

Doğan B, Harmanyeri Y, Baloğlu H, Oztek I

机构信息

GATA Haydarpaşa Teaching Hospital, Department of Dermatology, Istanbul, Turkey.

出版信息

Cancer Lett. 1995 May 8;91(2):215-9. doi: 10.1016/0304-3835(95)03741-e.

DOI:10.1016/0304-3835(95)03741-e

PMID:7767912

Abstract

Basal cell carcinoma (BCC) is an epithelial tumour of the skin that arises from basal cells of the epidermis and its appendages. There are some therapeutic models for BCC, and one of these is intralesional interferon. Thirteen patients with histopathologically-proven BCC on their faces or trunk were treated with intralesional interferon alfa-2a. Only 2 of 13 patients required surgery due to insufficient improvement. All the others were completely cured in 12 to 36 weeks. We concluded that intralesional interferon therapy of sufficient dose and duration for noduloulcerative and superficial BCC is an encouraging alternative to surgery and other treatment models.

摘要

基底细胞癌（BCC）是一种皮肤上皮肿瘤，起源于表皮及其附属器的基底细胞。BCC有一些治疗模式，其中之一是病灶内注射干扰素。对13例面部或躯干部位经组织病理学证实为BCC的患者进行了病灶内注射α-2a干扰素治疗。13例患者中只有2例因改善不足而需要手术。其他所有患者在12至36周内完全治愈。我们得出结论，对于结节溃疡性和浅表性BCC，给予足够剂量和疗程的病灶内干扰素治疗是一种令人鼓舞的手术及其他治疗模式的替代方法。